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Abstract
Introduction Int6 has been shown to be an interactive
participant with the protein translation initiation complex eIF3,
the COP9 signalosome and the regulatory lid of the 26S
proteasome. Insertion of mouse mammary tumor virus into the
Int6 locus creates a C-terminally truncated form of the protein.
Expression of the truncated form of Int6 (Int6sh) in stably
transfected human and mouse mammary epithelial cell lines
leads to cellular transformation. In addition, decreased
expression of Int6/eIF3e is observed in approximately one third
of all human breast carcinomas.
Methods To validate that Int6sh has transforming activity in vivo,
a transgenic mouse model was designed using the whey acidic
protein (Wap) promoter to target expression of truncated Int6 to
differentiating alveolar epithelial cells in the mammary gland.
Microarray analyses were performed on normal, premalignant
and malignant WapInt6sh expressing tissues.
Results Mammary tumors developed in 42% of WapInt6sh
heterozygous parous females at an average age of 18 months.
In WapInt6sh mice, the contralateral mammary glands from both
tumorous and non-tumorous tissues contained widespread
focal alveolar hyperplasia. Only 4% of WapInt6sh non-breeding
females developed tumors by 2 years of age. The Wap promoter
is active only during estrus in the mammary tissue of cycling non-
pregnant mice. Microarray analyses of mammary tissues
demonstrated that Int6sh expression in the alveolar tissue
altered the mammary transcriptome in a specific manner that
was detectable even in the first pregnancy. This Int6sh-specific
transcriptome pattern subsequently persisted in both the Int6sh-
expressing alveolar hyperplasia and mammary tumors. These
observations are consistent with the conclusion that
WapInt6sh-expressing alveolar cells survive involution following
the cessation of lactation, and subsequently give rise to the
mammary tumors that arise in aging multiparous females.
Conclusion These observations provide direct in vivo evidence
that mammary-specific expression of the Int6sh truncation leads
to persistence of alveolar hyperplasia with the accompanying
increased predisposition to mammary tumorigenesis.
Introduction
Int6/eIF3e (p48) was originally isolated from a mammary
hyperplastic outgrowth cell line derived from a preneoplastic
hyperplastic alveolar nodule (HAN), its tumors and metas-
tases, and two independently arising mammary tumors [1]. In
each clone, the mouse mammary tumor virus (MMTV) inte-
grated in an intron of one allele of Int6 in the reverse transcrip-
tional orientation to that of Int6, generating a chimeric mRNA.
Integration events were found in introns 5, 9 and 12 producing
different C-terminal truncations of Int6. The most extreme trun-
cation (in intron 5) produced an mRNA containing sequences
encoding the N-terminal 137 amino acids of Int6 (out of 445
amino acids), novel sequences from intron 5 upstream of the
integration site and reverse sequences from the MMTV 3' LTR
upstream of the cryptic stop signal, Int6 short (Int6sh). The
essentially random integration of retroviral DNA, and the fact
that Int6 was mutated in virtually the same way in multiple inde-
pendent tumors, suggests its potential role in malignant trans-
formation. No mutations in the remaining Int6 allele were
detected in these MMTV-induced tumors, and the expression
COP9 = constitutive photomorphogenesis 9 signalosome (CSN); eIF3 = eukaryotic translation initiation factor 3; GAPDH = glyceraldehyde 3-phos-
phate dehydrogenase; GFP = green fluorescent protein; HAN = hyperplastic alveolar nodule; LOH = loss of heterozygosity; LTR = long terminal 
repeat; MMTV = Mouse mammary tumor virus; MPN = Mpr-1-Pad-1-N-terminal domains; NLS = nuclear localization sequence; NSCLC = non-small 
cell lung carcinoma; PCI/PINT = 26S proteasome-COP9 signalosome-initiation factor 3/proteasome subunits-Int6-Nip-1-TRIP-15; RT-PCR = reverse 
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levels of full-length Int6 transcripts appeared unchanged, sug-
gesting that the truncation creates a dominantly acting
mutation.
Int6 has been highly conserved throughout evolution. It
encodes the p48 subunit of the eukaryotic translation initiation
factor-3, eIF3 subunit e. This large protein complex is respon-
sible for dissociating 80S ribosomes into subunits and pro-
moting the binding of methionyl-tRNA and mRNA to the 40S
ribosomal subunit during the initiation phase of protein synthe-
sis [2]. In fission yeast, Int6/eIF3e co-purifies with the eIF3
complex but is not essential for protein translation, suggesting
that this subunit plays a regulatory role [3,4]. Additional func-
tions emerging for Int6/eIF3e include regulating protein turno-
ver through its binding to the regulatory lid of the 26S
proteasome [5] and the COP9 signalosome [6]. Yin6 (yeast
ortholog of Int6) positively regulates the 26S proteasome,
which functions to degrade polyubiquitinated proteins, by
binding to and mediating the nuclear import and assembly of
another proteasome regulatory subunit, Rpn5 [7]. The result-
ing degradation of polyubiquitinated proteins is believed to be
essential for progression through the cell cycle. In addition to
the proteasome, Int6 also associates with the COP9 signalo-
some, CSN. In the single-celled yeast, the CSN regulates the
cell cycle checkpoint but in multi-cellular organisms, including
plants, it also participates in multiple developmental pathways,
which are all dependent on its control of ubiquitin-mediated
protein degradation by the proteasome [8,9]. The COP9 sig-
nalosome has been shown to have several additional activities:
de-ubiquitination, protein kinase and metalloprotease activi-
ties, each believed to be contributing to the regulation of ubiq-
uitin-proteasome-mediated protein degradation [10].
Direct evidence for the oncogenic activity of Int6sh in vitro
came from forced expression experiments showing that a trun-
cated form of Int6 can transform cells in culture [11]. Two
mammary epithelial cell lines, MCF10A (human) and HC-11
(mouse), expressing Int6sh from the elongation factor pro-
moter (eEF1a), exhibited anchorage-independent growth in
soft agar. Using slightly different criteria for cellular transforma-
tion, Mayeur and Hershey confirmed the in vitro transforming
activity of the Int6 truncation by stably transforming mouse
fibroblasts with a version of Int6 truncated after exon 4. They
also showed that fibroblasts expressing their truncated form of
Int6 were resistant to serum starvation-induced apoptosis
[12]. In addition, transplantation of MCF10A-Int6sh cells into
cleared fat pads of athymic mice led to the development of epi-
thelial nodules in half the fat pads. Similarly, HC11-Int6sh cells
produced lobular/alveolar structures at a rate of ~10% when
injected into cleared fat pads of Balb/c mice. When HC11-
Int6sh cells were transplanted into filled fat pads similar lobu-
lar/alveolar structures arose in 20% of the fat pads, suggest-
ing that the HC11-Int6sh cells could overcome local growth
regulatory control usually observed in a filled fat pad in a man-
ner similar to pre-malignant epithelial cells [11]. Taken
together, the in vitro and in vivo data strongly suggest an indi-
rect role for Int6 in proliferation and cell cycle control.
To determine whether the in vitro transforming ability of Int6sh
carries over to new in vivo tumor development, a transgenic
mouse line was created with mammary-specific Int6sh expres-
sion. The original preneoplastic mammary lesions and tumors
from which Int6sh was isolated harbored two to four additional
MMTV insertions. It remains possible that one or more of these
unidentified MMTV-induced mutations cooperated with the
Int6 truncation to produce the observed hyperplastic alveolar
nodules and tumors. To test this and model the role of the Int6
mutation in alveolar hyperplasia, we targeted Int6sh expres-
sion to the differentiating alveolar epithelium using the whey
acidic protein (Wap) promoter, which is under tight hormonal
regulation in the mouse mammary gland [13,14]. Wap expres-
sion occurs mainly during the secretory development of the
mammary gland during late pregnancy and during lactation.
Our WapInt6sh transgenic model demonstrates that ectopic
expression of a truncated form of Int6 from the Wap promoter
in the mammary epithelium results in persistent alveolar hyper-
plasia leading to mammary tumorigenesis.
Materials and methods
Generation and maintenance of WapInt6sh transgenic 
mice
A 472-bp HindIII/BamHI cDNA fragment encoding the trun-
cated form of Int6 (amino acids 1–137), with an in frame
hemagglutinin (HA) epitope tag at its C-terminus, was sub-
cloned immediately downstream of the 2.4-kb whey acidic
protein (Wap) promoter in pBluescript II SK+ (Stratagene, La
Jolla, CA, USA) (Figure 1). The construct was linearized, gel-
purified and microinjected into pronuclei of embryos from
FVB/N mice. Microinjected embryos were transferred to the
oviducts of pseudo-pregnant FVB/N females. Transgene-pos-
itive founder mice were identified by subjecting tail-snip
genomic DNA to PCR using the following primers to amplify a
602-bp Wap promoter/Int6sh junction fragment (Primers:
Wap promoter 2,281 forward, 5'-TGGCCAAGAAGGAAGT-
GTTGTAGCC-3'; HA Tag 2,883 reverse, 5'-GCGTAATCCG-
GTACGTCATATGGG-3'). Although two founders were
originally identified, female offspring from only one of the 14
founders (J1 male) showed consistent Int6sh mRNA expres-
sion by RT-PCR in their mammary glands during late preg-
nancy and bred successfully. Therefore, all results reported
herein are from one transgenic founder. This founder and its
progeny were backcrossed with FVB/N mice from our colony
that have been genetically isolated for more than 10 years. All
mice were housed in Association for Assessment and Accred-
itation of Laboratory Animal Care-accredited facilities in
accordance with the NIH Guide for the Care and Use of Lab-
oratory Animals.Available online http://breast-cancer-research.com/content/9/4/R42
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Mammary gland histology
Whole mounts of thoracic and inguinal mammary glands were
prepared by spreading the glands on a glass slide and fixing in
Carnoy's fixative (10% glacial acetic acid, 30% chloroform
and 60% absolute ethanol) for 4 h to overnight. Following
fixation, the glands were stained with 0.2% carmine alum,
washed with 70% ethanol for at least 30 min, followed by 95%
ethanol for at least 1 h. Glands were defatted in xylenes for at
least 30 min and mounted under coverslips using permount.
For histological examination, whole mounts were embedded in
paraffin, sectioned at 6.0 μm and stained with hematoxylin and
eosin.
For the analysis of mammary glands from
WapCreRosa26stopWapInt6sh mice, whole mounts were
fixed in 4.0% paraformaldehyde for 1–2 h, permeabilized in
0.01% Nonidet P-40 in PBS overnight at 4°C and incubated
with X-Gal substrate (1 mg/ml) overnight at 37°C. Stained
glands were repeatedly rinsed in PBS, postfixed in Carnoy's
fixative, dehydrated in 100% ethanol and cleared in xylenes.
For histological examination, X-Gal-stained glands were
embedded in paraffin, sectioned at 6.0 μm, and counter-
stained with nuclear fast red.
RNA preparation and RT-PCR
Mammary-specific Int6sh expression was then determined by
the RT-PCR amplification of a fragment spanning the Wap
promoter/Int6sh junction. RNA was prepared from wild-type
and Int6sh transgenic mammary glands using the Qiagen Lipid
Tissue Kit according to the manufacturer's protocol (Qiagen,
Valencia, CA, USA). DNaseI-treated total RNA (1 μg) was
subjected to the SuperScript™ First-Strand Synthesis System
for RT-PCR (Invitrogen, Carlsbad, CA, USA). Then, one tenth
of that reaction was amplified by target-specific linear PCR
(20–25 cycles) for GAPDH and Int6sh using Platinum Taq
DNA Polymerase (Invitrogen). Int6sh PCR primers were the
same as those employed for mouse genotyping. Control prim-
ers for the housekeeping gene, GAPDH were as follows: for-
ward, 5'-ACCACAGTCCATGCCATCAC-3'; reverse, 5'-
TCCACCACCCTGTTGCTGTA-3'. Band intensities on 1.2%
agarose gels reflected the relative amount of each transcript
present in the original sample.
To determine if Int6sh message was present in hyperplastic
alveolar nodules, HANs were dissected away from the sur-
rounding normal mammary gland and total RNA from the
tumor, HANs and normal tissue were amplified separately.
Equal amounts of total RNA were used in each first-strand syn-
thesis reactions, followed by the target-specific PCR method
outlined above.
Microarray analysis
Additional file 1 summarizes the pooling scheme from wild-
type and transgenic mammary glands and two of the three
Figure 1
Int6 functional domains and wapint6sh transgenic construct Int6 functional domains and wapint6sh transgenic construct. A schematic of the Int6 protein is shown: NES, nuclear export signal; internal ATGs 
denote alternative start sites located approximately 40 amino acids downstream of the predominant start site; NLS, bipartite nuclear localization 
sequences at amino acid numbers 268 and 310; PCI/PINT domain, proteasome, COP9 signalosome, initiation factor 3/proteasome subunits, Int-6, 
Nip-1 and TRIP-15 domain characteristic of proteins that make up the proteasome, signalosome and translation initiation complexes. The number of 
amino acids in each protein is shown below the bars. The extent of the Int6sh truncation is shown for comparison. The construct used to generate 
the WapInt6sh transgenic mice is shown at the bottom. A PCR-amplified HindIII/BamHI fragment was cloned downstream of the 2.4 kb Wap pro-
moter fragment in pBluescript SK+. HA Tag, hemagglutinin epitope tag. The line at the lower right designates the 602-bp junction fragment ampli-
fied by RT-PCR. The sizes of DNA fragments are not drawn to scale.Breast Cancer Research    Vol 9 No 4    Mack et al.
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tumor types and shows the microarray hybridizations per-
formed. Total RNA was prepared from each gland separately,
quantitated and quality tested. Only then was the same
amount of RNA (1 μg) combined to make an individual pool.
From each pool 1 μg of total RNA was converted into labeled
cRNA with nucleotides coupled to a fluorescent dye (either
Cy3 or Cy5) using the Low RNA Input Linear Amplification Kit
(Agilent Technologies, Palo Alto, CA, USA) following the man-
ufacturer's protocol. The quality and quantity of the resulting
labeled cRNA was assessed using a NanoDrop ND-1000
spectrophometer (NanoDrop Technologies, Wilmington, DE,
USA) and an Agilent 2100 Bioanalyzer. Equal amounts of Cy3
and Cy5-labeled cRNA (750 ng) from two different samples
were hybridized to mouse microarrays (Agilent Mouse Oligo
Microarrays, G4121A) for 17 h at 60°C. The hybridized array
was then washed and scanned using an Agilent G2565AA
scanner. Data was extracted from the scanned image using
Feature Extraction v. 7.1 or 7.5 (Agilent Technologies; Red-
wood City, CA, USA) and analyzed using GeneSpring v. 7.2
software (Agilent Technologies). Each hybridization was per-
formed in duplicate in the form of Cy3/Cy5 dye flips (Addi-
tional file 1) and a standard deviation was calculated for each
pairwise comparison (data not shown). This limited statistical
power made it essential for us to validate the microarray data
via quantitative RT-PCR.
Validation of microarray data by qRT-PCR
Equal amounts of total RNA from wild-type and transgenic
mammary glands (distinct from that prepared for the micro-
array hybridizations) were pooled as outlined in Additional file
1 and then treated with DNaseI. Each pooled sample was then
quantitatively converted to single stranded cDNA using the
High-Capacity cDNA Archive Kit (Applied Biosystems). The
reaction from each pool was then quantitated using a Nano-
Drop spectrophotometer and 100 ng of the cDNA reaction
products were added to 18 individual target-specific TaqMan
Gene Expression Assays (TaqMan MGB probes, FAM dye-
labeled according to the manufacturer's protocol) using
GAPDH and ACTB as endogenous references and TaqMan
Universal PCR Master Mix (Roche Molecular Systems, NJ,
USA). All reactions were performed using a 96-well format on
a Stratagene Mx3000P Quantitative PCR Instrument and ana-
lyzed using MxPro software v. 3.0. Reactions for the endog-
enous controls were performed in quadruplicate while the
target-specific reactions were performed in duplicate. Stand-
ard curves over six orders of magnitude were performed to
confirm that the amplification efficiencies of all target genes
were similar to both endogenous controls. The comparative CT
method for relative quantitation was employed to generate
fold-change values for each of the 18 genes, normalized inde-
pendently against GAPDH and ACTB. Statistical analyses
were performed according to the manufacturers guidelines
(Real-Time PCR Systems Chemistry Guide, Applied
Biosystems).
Results
WapInt6sh transgenic founders transgene expression 
and tumorigenesis
Figure 1 shows a schematic of the functional domains of Int6
indicating those deleted in the truncated transgenic construct.
A total of 14 WapInt6sh founder mice and their first generation
offspring were screened by RT-PCR for mammary-specific
Int6sh expression. Four founder females expressed Int6sh in
their mammary glands, but all late pregnant female offspring
failed to consistently express Int6sh. Five female offspring from
one founder male (J1) consistently showed Int6sh expression
in their mammary glands and successfully passed the trans-
gene to their progeny. As expected, the whey acidic protein
(Wap) promoter successfully targeted expression of Int6sh to
mammary epithelial cells. Additional file 2 demonstrates that
expression of the transgene was induced in pregnant females
at approximately day 15 of gestation with sustained expression
through parturition and early involution. The J1 founder male
and his female offspring were backcrossed to wild-type FVB/
N mice to generate the F1s that were then interbred to pro-
duce the mice analyzed in this study. The original J1 founder
male developed a testicular tumor (where Wap expression has
also been demonstrated [15]), and metastases in the liver and
pancreas, all of which tested positive for Int6sh expression
(data not shown).
WapInt6sh multiparous females developed persistent 
hyperplastic alveolar nodules and mammary tumors 
consistent with malignant progression
Heterozygous transgenic Int6sh female FVB/N mice devel-
oped tumors at a frequency of 41.7% (10/24) around 18
months of age after giving birth to several (2–4) litters (Table
1). Despite a long tumor latency, these tumors grew quite rap-
idly once established. Prior to tumor formation, the multiparous
Int6sh transgenic female mice were able to reproduce and to
lactate normally. Histologically, three types of the tumors arose
in the Int6sh multiparous females. One contained only undiffer-
entiated epithelia, a second group showed characteristics of
papillary adenocarcinoma while a third group appeared more
glandular (Figure 2). The incidence of each tumor type was
approximately equal (tumor incidence data are summarized in
Additional file 3). In contrast to multiparous females, only one
nulliparous Int6sh transgenic female mouse of the same age
developed a tumor (1/26 = 3.8%), consistent with the
decreased expression of the Wap promoter in nulliparous
females. This tumor histologically resembled the papillary ade-
nocarcinomas. In an earlier study from our lab, 22 multiparous
female FVB mice (from the same FVB inbred subline used to
construct the WapInt6sh model) were held for tumor inci-
dence for more than 2 years with no spontaneous mammary
tumors [16]. The Fisher's exact test p value reported for the
tumor incidence comparison between the wild-type multipa-
rous littermates and WapInt6sh multiparous females, p =
0.035, is probably conservative given the historical multipa-
rous controls with a p value of 0.0006. Based on the low mam-Available online http://breast-cancer-research.com/content/9/4/R42
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mary tumor incidence reported in the bulk of the literature
(summarized in [17]), the equally low spontaneous mammary
tumor incidence in multiparous FVB female mice in our iso-
lated colony [18], the identification of the MMTV-induced Int6
truncation in a pre-neoplastic mammary lesion and the ability
of Int6sh to transform cells in culture, we believe these tumors
were a direct result of expression of Int6sh.
Multiple focal alveolar hyperplasias were also frequently
observed in the non-tumor-containing mammary glands of the
same 15–22-month-old retired breeders (Figure 3a,b). The
presence of these hyperplastic alveolar nodules (HANs) reca-
pitulated the phenotype observed in the mammary glands of
mice harboring the original MMTV insertion in Int6 [1]. Int6sh-
induced hyperplasia persisted in multiparous females well
after involution (see Figure 3a,b, with 25 × inset, and 25 ×
magnification of an HAN shown in c) and could be premalig-
nant populations. Higher magnification of HANs frequently
showed extensive lymphocytic infiltration (Figure 3c). Approx-
imately 80% of retired Int6sh breeders (with two or more lit-
ters) displayed the focal hyperplastic phenotype in an
otherwise normally involuted gland (Figure 3a,b). In contrast,
mammary glands from the other 20% of Int6sh multiparous
females failed to involute at all or showed a marked delay in
involution over the whole gland as long as 15 months after
their last litter was weaned (Figure 3d). All tumors, regardless
of tumor type, arose in mice that had focal or global hyperpla-
sia in their contralateral glands. Additional file 3 documents the
frequency and type of hyperplasias in all 24 transgenic mice
analyzed.
To more directly demonstrate that the population of cells form-
ing hyperplasia arose from alveolar epithelium surviving involu-
tion after lactation, the WapInt6sh mouse was crossed with
the WapCreRosa26stop mouse. Previous work from our labo-
ratory identified a LacZ-tagged population of parity-induced
mammary epithelial cells (PI-MECs) that is pluripotent and has
the ability to self-renew [14]. Committed alveolar cells will also
express  β-galactosidase after conditional activation by the
Cre-lox recombinase, which is driven by the Wap promoter. If
both PI-MECs and fully committed alveolar cells survive invo-
lution because of Int6sh expression then the number and per-
sistence of LacZ-positive cells following the cessation of
lactation should increase. Parous
WapCreRosa26stopWapInt6sh  females developed foci of
LacZ-positive alveolar cells, which survived post-lactation
involution confirming that mammary epithelial cells formed dur-
ing pregnancy persistently survived in WapInt6sh-expressing
mammary glands. Additional file 4 shows the no. 3 mammary
glands from two different multiparous
WapCreRosa26WapInt6sh mice, one at 4 months (a and c)
and the other at 6 months of involution (b and d). The X-Gal
stained whole mounts (a and b) clearly show multiple LacZ+
focal hyperplasias after several months of involution, similar to
the WapInt6sh transgenic. Higher magnification images (c
and d, 200 ×) of two different focal areas of hyperplasia show
LacZ+ luminal epithelial cells interspersed with LacZ negative
cells. In an earlier report, our laboratory demonstrated that PI-
MECs were targets for MMTV-ErbB2 induced mammary can-
cer [19]. Therefore the persistent survival of an alveolar popu-
lation from one pregnancy through the next represents a
Table 1
Mammary tumor incidence in WapInt6sh female transgenic mice compared with wild-type female FVB/N mice at 24 months of age.
Strain and genotype No. of mice with tumors Total mice (N) Tumor incidence (%) Fisher's exact test p value Reference
FVB/N wild-typea 0 71 0 <0.00001b [17]
FVB/N wild-type, multiparousc 0 22 0 0.0006d [16]
FVB/N WapInt6sh virgins 1e 26f 3.8% 0.0016g This work
FVB/N wild-type, multiparoush 0 8 0 0.035i This work
FVB/N WapInt6sh, multiparous 10j 24k 41.7% NA This work
aReported by the National Institute for Environmental Health Sciences. For this comparison, only histological malignant lesions were scored as 
tumors; adenomas and other benign lesions were not included.
bp < 0.00001 from the Fisher's exact test of previously published tumor incidence in FVB/N wild-type mice vs WapInt6sh multiparous females 
(row 1 vs row 5).
cIncludes all frank tumors classified histopathologically as adenomas or adenocarcinomas.
dp = 0.0006 from the Fisher's exact test of previously published tumor incidence in FVB/N wild-type multiparous mice vs WapInt6sh multiparous 
females (row 2 vs row 5).
eHistologically, a papillary adenocarcinoma
fTotal mice included 21 heterozygous and 5 homozygous WapInt6sh transgenic mice from J1 founder line that survived 24 months or longer.
gp = 0.0016 from the Fisher's exact test of WapInt6sh virgins vs WapInt6sh multiparous females (row 3 vs row 5).
hIncludes multiparous FVB/N wild-type littermates resulting from WapInt6sh heterozygous crosses. Each mouse is identified in Additional file 3.
ip = 0.035 from the Fisher's exact test of wild-type multiparous vs WapInt6sh multiparous females (row 4 vs row 5).
jOf the 11 tumors arising in 10 multiparous transgenic females, there were 4 undifferentiated tumors, 5 papillary adenocarcinomas and 2 glandular 
adenocarcinomas.
kTotal mice included both heterozygous or homozygous WapInt6sh transgenic mice from J1 founder line that lived to tumor age (>12 months) and 
produced >1 litter.Breast Cancer Research    Vol 9 No 4    Mack et al.
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premalignant population that exhibits an increased
predisposition for tumor development as demonstrated earlier
for mice transgenic for mammary-specific transforming growth
factor alpha (TGF-α) [16]. In agreement with this hypothesis,
WapInt6sh-induced tumor development is accentuated by
multiple pregnancies.
Transgenic Int6sh is expressed in mammary tumors and 
hyperplasias
To determine the relative expression levels of Int6sh mRNA in
transgenic mammary glands and tumors semi-quantitative RT-
PCR was used. Figure 4a shows the linear amplification of a
fragment spanning the Wap promoter and Int6sh transgene
junction (see also Figure 1) relative to the expression of the
GAPDH housekeeping gene. As expected, Int6sh expression
is not present in the wild type (lane 1) nor the virgin mammary
glands (lane 2) but is induced in late pregnancy (lane 3b). The
tumor arising in a virgin Int6sh transgenic did not express
detectable levels of Int6sh (lane 4), suggesting that growth of
this tumor is not dependent on Int6sh expression. Uniformly
hyperplastic glands and glands containing multiple focal
hyperplasias also express varying amounts of Int6sh mRNA
(lanes 6–9) indicating that either expression from the Wap
promoter is maintained in the lobular structures.
Figure 4b shows the results of Int6sh mRNA amplification from
the two non-tumor-containing inguinal mammary glands and a
mammary tumor arising in the right no. 5 mammary gland
dissected from an Int6sh retired breeder. The surrounding nor-
mal tissue showed barely detectable levels of Int6sh while the
focal hyperplasias and tumor showed higher expression (lanes
10–12). Likewise, all the tumors, whether undifferentiated or
adenocarcinomas, showed high levels of Int6sh expression
(lanes 13–16) indicating that the Wap promoter remained
constitutively activated both in the tumors and in the alveolar
hyperplasia. A high level of Int6sh expression was also
observed in hyperplastic outgrowths that resulted after trans-
genic tumor fragments were transplanted into the epithelium-
divested fat pads of non-pregnant, wild-type recipients (lanes
17,18).
Gene expression profiling of Int6sh-induced 
hyperplasias and tumors
To establish a potential mechanism for the action of Int6sh in
the tumorigenic process, microarray analysis was performed in
an attempt to gain insight into what processes or pathways
might be altered by the presence of truncated Int6. To
accomplish this, mammary RNA from Int6sh-expressing per-
sistent hyperplasia was compared with mammary RNA from
age- and parity-matched pregnant and non-pregnant wild-type
females in order to detect presumptive gene expression alter-
ations associated with persistent Int6sh-induced hyperplasia.
In addition, RNA was extracted from first pregnancy wild-type
and Int6sh transgenic mice to determine if the same pattern of
gene expression could be detected even earlier, before phe-
Figure 2
Representative histopathologies of three different types of mammary  tumors arising in WapInt6sh multiparous females Representative histopathologies of three different types of mammary 
tumors arising in WapInt6sh multiparous females. The top panel shows 
an undifferentiated tumor; the middle panel shows the features of a 
papillary adenocarcinoma, including fibrovascular stalks covered in 
neoplastic epithelium; the bottom panel is more indicative of a glandular 
adenocarcinoma. Sections 5 μm thick were hematoxylin and eosin 
stained and photographed at 200 × magnification. A 10-μm bar is 
shown at the lower right of each panel.Available online http://breast-cancer-research.com/content/9/4/R42
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notypic changes were evident. To detect gene expression dif-
ferences as pre-neoplastic hyperplasia progresses to tumor,
the same RNA from Int6sh-expressing hyperplasia was hybrid-
ized against RNA from the two Int6sh tumor types. Additional
file 5 summarizes the microarray comparisons and sample-
pooling scheme. Genes coordinately regulated throughout
tumorigenesis were identified by comparing in silico the 121-
member gene list identified during the pre-neoplastic phase to
the 525-member gene list found during the tumor phase. Fig-
ure 5a outlines how each comparison was performed and the
number of genes identified as at least twofold up and down-
regulated in each pairwise comparison. Unsupervised hierar-
chical cluster analysis produced a list of 59 genes that are
coordinately regulated during Int6sh-induced tumorigenesis is
shown in Figure 5b. Approximately twice as many genes were
at least twofold upregulated as downregulated, which might
not be surprising given the increased metabolic activity of the
tumors. Of the genes identified, 22 (37%) have been previ-
ously associated with mammary tumorigenesis (denoted by
the asterisks). Using the gene ontology database within the
GeneSpring software and gene ontology annotations [20], 38
of the 59 genes could be assigned to seven functional groups
with 4–7 members per group. Genes involved in protein deg-
radation, solute transport, neurogenesis, energy metabolism
and lipid, adipose, fatty acid metabolism always cluster
together as being upregulated while genes involved with cell
cycle regulation and chromosome management were consist-
ently downregulated during the progression to pre-neoplastic
lesion and then to frank tumor. Interestingly, protein degrada-
tion and chromosome management overlap with functions pre-
viously associated with full length Int6 in other model
organisms. The expression pattern of the 18 transcripts
involved with protein turnover, cell cycle regulation and chro-
mosome segregation have been confirmed by quantitative RT-
PCR (see Additional file 1 for the results of the qRT-PCR anal-
ysis compared to the annotated microarray heat map shown in
Figure 5).
The striking correspondence of gene expression patterns from
RNA isolated from the initial pregnancy in WapInt6sh glands
with those found in RNA from the persistent alveolar
hyperplasia and from the tumor sets argues that the hyperpla-
Figure 3
Mammary glands from multiparous WapInt6sh transgenic females show persistent alveolar hyperplasia Mammary glands from multiparous WapInt6sh transgenic females show persistent alveolar hyperplasia. (a) Multiple focal alveolar hyperplasias 
(green arrows) are visible in this carmine alum stained whole mounted mammary gland from a multiparous WapInt6sh transgenic female. LN, lymph 
node. Magnification 10 ×. (b) A no. 4 mammary gland from a WapInt6sh multiparous female containing one focal hyperplasia at 10 × magnification. 
Inset panel shows the hyperplasia at higher magnification (25 ×). This gland and the gland shown in Panel A were each taken from mice with tumors 
in their contralateral no. 4 mammary glands. (c) Hematoxylin and eosin-stained 5 μm section through the focal hyperplasia shown in Panel B. Well 
defined acinar structures are visible at 100 × magnification surrounded by significant lymphocytic infiltration (green arrows). (d) Representative mul-
tiparous WapInt6sh mammary gland showing a more uniform persistence of alveolar hyperplasia. This female had three litters, the last of which was 
weaned 9 months before this gland was harvested.Breast Cancer Research    Vol 9 No 4    Mack et al.
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sia is formed from an alveolar epithelial population that sur-
vives post-lactational involution and tissue remodeling.
Furthermore, this signature pattern was maintained and
strengthened in the tumor RNA suggesting strongly that the
tumors arise from the hyperplastic alveolar cells.
To validate the microarray data, quantitative RT-PCR was per-
formed on 18 of the 59 Int6sh tumorigenesis signature genes.
This subset of genes was chosen because of their role in tum-
origenesis in other cell culture-based and transgenic tumor
models and because of their association with previously doc-
umented Int6 functions. The results of the qRT-PCR are pre-
sented in Additional file 1 along with a comparison to the
microarray raw numbers that produced the heat map in Figure
5b. Two different endogenous controls (GAPDH and ACTB)
were employed to reduce variability that might exist between
normal, hyperplastic and tumor-containing mammary tissues.
The mRNA quantitation of 14 of these 18 genes closely mir-
rored the results of the microarray analysis in terms of up or
downregulation and fold-change value, while the expression of
the remaining four genes were corroborated in direction of
change only. In general, the microarray data under estimated
the extent of up or downregulation compared to the qRT-PCR
for approximately 50% of the genes analyzed. As these genes
were chosen for their role in tumorigenesis and their connec-
tion to Int6 function, independent of their up or downregulation
or fold-change value, it stands to reason that the same degree
of validation could then be applied to the remaining 41 genes
in the Int6sh signature transcriptome.
Discussion
Our observations conclusively demonstrate that targeted
expression of the Int6sh mutation to mammary epithelium in
vivo results in a significant increase in mammary cancer risk.
These data provide a strong validation of Int6sh as an onco-
genic mutation in mammary epithelium. Although large C-ter-
minal deletions often lead to loss of function, the most
frequently suggested mechanism for Int6sh action is as a dom-
inantly acting mutation. This idea is consistent with the obser-
vation that interruption (and truncation) of the Int6 gene in
MMTV-induced hyperplasia and tumors occurs by proviral
DNA insertion in several different introns, any of which could
produce a dominant allele. Despite this evidence, it remains
formally possible that Int6 haploinsufficiency caused by MMTV
integration in the originally isolated hyperplastic outgrowth cell
line and the two independent tumors was the cause of the pre-
malignant and malignant phenotypes. Frequent loss of
heterozygosity (LOH) of Int6 in both breast and non-small cell
lung carcinomas (NSCLC) [21,22] and decreased expression
of Int6 through hypermethylation of the promoter and first exon
in NSCLC [23] suggest that normal Int6 function might be
sensitive to the level of expression. However, the transgenic
model reported here demonstrates that the targeted expres-
sion of a truncated form of Int6 is sufficient to produce
persistent mammary hyperplasia and an increased incidence
of mammary tumors in a background of normal wild-type Int6
expression. Indeed throughout the Int6sh tumor progression,
endogenous Int6 expression is unchanged as shown in its
microarray single-gene expression tracing (Additional file 6).
Therefore, in our WapInt6sh model of mammary tumorigene-
sis, haploinsufficiency does not play a role.
The presence of Int6sh RNA has an immediate impact upon
the transcriptome of late pregnant mammary tissue as demon-
strated by our microarray analysis. Strikingly, the changes
manifest in the WapInt6sh mammary RNA at first pregnancy
are emboldened in the RNA isolated from the alveolar hyper-
plasia that persists in WapInt6sh parous females. This indi-
cates that there is preferential survival of Int6sh-expressing
alveolar cells following the cessation of lactation. Int6sh-
induced tumors arise as a consequence of a persistent alveo-
lar hyperplasia that morphologically resembles pregnant lobu-
lar/alveolar mammary tissue. The persistence of this cell type
Figure 4
WapInt6sh relative expression levels determined by linear RT-PCR WapInt6sh relative expression levels determined by linear RT-PCR. The 
top panel shows the relative expression of Int6sh in various wild-type 
and transgenic mammary glands at different stages of development. 
Expression of the housekeeping gene, GAPDH is shown for compari-
son. The level of expression of Int6sh in lanes 6–9 is proportional to the 
extent of hyperplasia observed in those glands. The bottom panel 
shows Int6sh expression from dissected portions of the mammary 
glands of one mouse (no. 1,581, lanes 10–12), from independently 
arising tumors (lanes 13–16) and from outgrowths arising after trans-
planting tumor fragments (lanes 17,18). Histologically 'normal' mam-
mary tissue (shown in lanes 10, a and b) was dissected away from 
surrounding focal hyperplasias and tumor tissue and then pooled. 
Transplantation of parous WapInt6sh tumor fragments into mammary 
epithelium-divested fat pads produced outgrowths that expressed 
detectable amounts of Int6sh RNA, suggesting that they also arose 
from mammary cells constitutively expressing the transgene (lanes 
17,18). First strand reactions without RT and those with RT are desig-
nated as a and b respectively.Available online http://breast-cancer-research.com/content/9/4/R42
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might be linked to a decrease in the rate of apoptosis during
involution, consistent with the observation of Mayeur et al. that
fourfold fewer Int6sh-expressing fibroblasts go through
apoptosis compared to wild-type control cells or cells express-
ing only full-length Int6 [12]. Subsequently, mammary tumors
arise in these glands and analysis bears out that the tumor
transcriptome bears many features of the normal and hyper-
plastic Int6sh-expressing tissues. These results provide strong
evidence for the linear progression of Int6sh-expressing epi-
thelium from normal through hyperplasia to tumor formation.
The long tumor latency coupled with the observation that the
tumors arose stochastically (usually only one gland per mouse
was affected) suggests that other genetic or epigenetic
events were required for initiation or progression of tumor
growth. We therefore compared gene expression in mammary
tissues where Int6sh was expressed with expression profiles
in age and developmental stage-matched wild-type mammary
tissue. The 59 genes comprising the Int6sh-induced tumori-
genic gene expression signature include 22 genes that have
been previously associated with mammary tumorigenesis (Fig-
ure 5).
The Int6sh-induced tumorigenesis gene list contains several
genes that participate in cellular processes that have been
linked to full length Int6 function in other model systems (Fig-
ure 5b). The most notable example is the consistent upregula-
tion of two components of the COP9 signalosome, namely
Cops5 (CSN5/Jun activation domain-binding protein 1, Jab1)
and Cops4 (CSN4), in both pre-neoplastic mammary glands
and tumors. In addition, four other proteins involved with pro-
tein turnover (γ-synuclein, 70 kDa heat shock protein 12A,
cathepsin R and inner mitochondrial membrane peptidase 2-
like) were also consistently upregulated during this tumor pro-
gression. Neither CSN5 nor CSN4 have been shown to
directly interact with Int6 in the signalosome, but several lines
of evidence make their association with Int6sh tumorigenesis
intriguing. CSN4 is less well studied but is believed to mediate
assembly of the CSN holocomplex through its PCI domain,
which it shares with Int6. CSN5 is by far the most studied
component of the COP9 signalosome having been linked to
tumor initiation and progression through maintenance of DNA
fidelity, cell cycle control, DNA repair, regulation of apoptosis,
angiogenesis and microenvironmental homeostasis [24].
Several other gene ontological groups showed consistent
upregulation throughout Int6sh tumorigenesis, including four
closely related solute carrier family members (Slc1a5, Slc2a4,
Slc2a5 and Slc7a10) and four neurogenesis/neuronal axon
outgrowth molecules (Netrin-G1, Tomoregulin, Semaphorin
cytoplasmic domain associated protein 2 and Ntrk2). Ducts
within Int6sh-expressing mammary glands, that did not
develop tumors, showed multiple morphological defects
including decreased secondary branching and termination at
blood vessels (data not shown). It is possible that the abnor-
mally high expression of several neuronal guidance transcripts
contributes to the defects in allometric ductal growth.
Two consistently downregulated gene ontological groups
were also identified during the Int6sh-induced progression
from pre-neoplastic lesion to frank tumor. There was a group
of five genes involved in cell cycle regulation, with four of the
genes always downregulated, including Gtse1 (a microtubule-
associated regulator of p53), Shcbp1 (a Shc SH-2 domain
binding protein), Cdc2a (also called CDK1, an Hsp70 binding
protein involved in the mitotic G2 checkpoint) and Cdkn1a (a
cyclin-dependent kinase inhibitor, also called p21/Waf/Cip1).
Several studies have linked the CSN to the regulation of the
cellular proliferation machinery. Molecules connecting these
two processes include the cyclin-dependent kinase inhibitors
p27/Kip1 [25] and p21/Waf/Cip1 [26], as well as cyclins D1
[27,28] and E [29,30]. In addition, Kato and colleagues
recently showed that in the CSN5 knock-out there were ele-
vated levels of the cell cycle regulatory genes p27/Kip1, p53
and cyclin E [31]. As a result, cell proliferation is impaired and
apoptosis is accelerated. However, in our tumorigenic model
CSN5 is upregulated as a result of Int6sh expression, possibly
causing a decrease in p21 (as observed), p53 and cyclin E
levels leading to increased proliferation and survival of a pop-
ulation of mammary epithelial cells.
Gene expression profiling of Int6sh-expressing hyperplasias and tumors Gene expression profiling of Int6sh-expressing hyperplasias and tumors. (a) Total RNA from wild-type, hyperplasia-containing and tumor-containing 
transgenic mammary glands was prepared and pools were made consisting of five mice each. The following comparisons were performed on Agilent 
Mouse 22 K 60-mer Oligo Arrays (G4121A): wild-type pregnant mammary glands vs Int6sh transgenic mammary glands at 18 months of age con-
taining persistent hyperplasia; non-pregnant wild-type age/parity-matched mammary glands vs Int6sh persistent hyperplastic glands; Int6sh hyper-
plastic glands vs undifferentiated tumors and Int6sh hyperplastic glands vs adenocarcinomas. The colored spheres show the number of genes that 
are at least twofold up or downregulated in each one of these comparisons. The numbers in the intersected spaces denotes genes that are common 
to any particular pairwise comparison. (b) The expression heatmap and gene list at the bottom of the figure shows those genes found to be coordi-
nately regulated throughout Int6sh-induced mammary tumorigenesis. The GeneSpring expression clustering algorithm was employed to determine 
which genes show the same pattern of expression in the four conditions, denoted A, B, C and D, corresponding to the comparisons shown in (a). 
The color bar on the left shows how hue relates to direction and extent of the transcriptional differences. Functional groups font color key: dark 
orange, protein folding and degradation; light blue, solute transporters; purple, neuronal guidance; red, energy metabolism; lime green, adipose, lipid 
and fatty acid metabolism; dark blue, cell cycle regulation; green, chromatin architecture and chromosome segregation. Asterisks denote genes that 
have been previously implicated in mammary tumorigenesis.
Figure 5Available online http://breast-cancer-research.com/content/9/4/R42
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Conclusion
The Int6sh transgenic mouse model presented here provides
the first and to date only in vivo evidence that the expression
of truncated Int6 leads to persistent mammary hyperplasia and
increased predisposition to mammary tumors. The immediate
effect that expression of truncated Int6 has on the transcrip-
tome of the differentiating alveolar mammary epithelium
suggests that further study regarding this aspect of Int6sh
expression could provide a useful mechanism for
understanding the complex function(s) of Int6 in translation ini-
tiation, the COP9 signalosome and the proteasome.
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